Article
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
The oncologist - 11 Mar 2022
Sturgill Emma G, Misch Amanda, Jones Carissa C, Luckett Daniel, Fu Xiaotong, Schlauch Dan, Jones Suzanne F, Burris Howard A, Spigel David R, McKenzie Andrew J
Abstract excerpt
BACKGROUND: Tumor mutation burden (TMB), a biomarker for immune checkpoint inhibitor (CPI) response, is reported by both blood- and tissue-based next-generation sequencing (NGS) vendors. However, the agreement between TMB from blood (bTMB) and tissue (tTMB) in real-world settings, both in absolute value and association with CPI response, is not known. MATERIALS AND METHODS: This study utilizes Sarah Cannon's...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.